Market Overview

UPDATE: Jefferies & Company Reiterates Buy Rating, Lowers PT for Valeant Pharmaceuticals International

Related VRX
Benzinga's M&A Chatter for Tuesday November 18, 2014
Bill Ackman Says He Supports The Allergan-Actavis Deal And CEO Brent Saunders
Deal Frenzy: 2014 Sees Record M&A Volume (Fox Business)

In a report published earlier today, Jefferies & Company, Inc. reiterated its Buy rating for Valeant Pharmaceuticals International, Inc. (NYSE: VRX), but lowered its price target from $75.00 to $63.00.

Jefferies went on to say “After what we viewed as an excellent analyst day yesterday, VRX remains controversial ... yet an excellent investment -- especially after yesterday's weakness. For a company with >20% exposure in Europe, to actually reaffirm the UPPER end of its EPS guidance is a testament to the strength and durability of its business model. We now lower our PT for a more realistic market.”

Valeant Pharmaceuticals International, Inc. closed yesterday at $45.23.

Latest Ratings for VRX

DateFirmActionFromTo
Oct 2014Cantor FitzgeraldMaintainsBuy
Oct 2014JefferiesMaintainsBuy
Aug 2014Cantor FitzgeraldMaintainsBuy

View More Analyst Ratings for VRX
View the Latest Analyst Ratings

Posted-In: Jefferies & Company Inc.Analyst Color Price Target Reiteration Analyst Ratings

 

Related Articles (VRX)

Around the Web, We're Loving...

Get Benzinga's Newsletters